Beta blocker therapy is associated with reduced depressive symptoms 12 months post percutaneous coronary intervention

Linda Battes, Susanne Pedersen, Rohit Oemrawsingh, Robert Jan van Geuns, I Al Amri, Evelyn Regar, Peter de Jaegere, PWJC (Patrick) Serruys, Ron van Domburg

Research output: Contribution to journalArticleAcademicpeer-review

13 Citations (Scopus)


Background: Beta blocker therapy may induce depressive symptoms, although current evidence is conflicting. We examined the association between beta blocker therapy and depressive symptoms in percutaneous coronary intervention (PCI) patients and the extent to which there is a dose-response relationship between beta blocker dose and depressive symptoms. Methods: Patients treated with PCI (N = 685) completed the depression scale of the Hospital Anxiety and Depression Scale 1 and 12 months post PCI. Information about type and dose of beta blocker use was extracted from medical records. Results: Of all patients, 68% (466/685) were on beta blocker therapy at baseline. In adjusted analysis, beta blocker use at 1 month post PCI (OR: 0.82; 95% CI: 0.53-1.26) was not significantly associated with depressive symptoms. At 12 months post PCI, there was a significant relationship between beta blocker use and depressive symptoms (OR: 0.51; 95% CI: 031-0.84), with beta blocker therapy associated with a 49% risk reduction in depressive symptoms. There was a dose-response relationship betwe Conclusions: Patients treated with beta blocker therapy were less likely to experience depressive symptoms 12 months post PCI, with there being a dose-response relationship with a higher dose providing a more pronounced protective effect. (C) 2011 Elsevier B.V. All rights reserved.
Original languageUndefined/Unknown
Pages (from-to)751-757
Number of pages7
JournalJournal of Affective Disorders
Issue number3
Publication statusPublished - 2012

Cite this